Limits...
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Patti F - Patient Prefer Adherence (2010)

Bottom Line: Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy.Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy.This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, University of Catania, Catania, Italy.

ABSTRACT
Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.

No MeSH data available.


Related in: MedlinePlus

Factors leading to poor adherence to multiple sclerosis therapy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2819898&req=5

f1-ppa-4-001: Factors leading to poor adherence to multiple sclerosis therapy.

Mentions: In MS, it is currently unclear precisely what effect the degree to which patients adhere to therapy has on clinical or magnetic resonance imaging outcomes, but patients who do not adhere to therapy are unlikely to receive the full potential benefit of treatment,8 and therefore may be at increased risk of poorer outcomes. A study that investigated the relationship between the duration of gaps in MS treatment regimens and the incidence of severe MS relapses found that patients who had gaps in therapy lasting ≥90 days had a nearly twofold greater probability of experiencing a severe relapse than patients with shorter gaps in therapy.29 This shows the importance of adherence to prescribed regimens for MS. Potential barriers to treatment adherence in MS are summarized in Figure 1. All of these issues can affect the patient’s quality of life, whether they relate to features of the disease, or to the treatment itself. It may be speculated that poor overall quality of life may affect the individual patient’s likelihood of adherence to therapy.


Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Patti F - Patient Prefer Adherence (2010)

Factors leading to poor adherence to multiple sclerosis therapy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2819898&req=5

f1-ppa-4-001: Factors leading to poor adherence to multiple sclerosis therapy.
Mentions: In MS, it is currently unclear precisely what effect the degree to which patients adhere to therapy has on clinical or magnetic resonance imaging outcomes, but patients who do not adhere to therapy are unlikely to receive the full potential benefit of treatment,8 and therefore may be at increased risk of poorer outcomes. A study that investigated the relationship between the duration of gaps in MS treatment regimens and the incidence of severe MS relapses found that patients who had gaps in therapy lasting ≥90 days had a nearly twofold greater probability of experiencing a severe relapse than patients with shorter gaps in therapy.29 This shows the importance of adherence to prescribed regimens for MS. Potential barriers to treatment adherence in MS are summarized in Figure 1. All of these issues can affect the patient’s quality of life, whether they relate to features of the disease, or to the treatment itself. It may be speculated that poor overall quality of life may affect the individual patient’s likelihood of adherence to therapy.

Bottom Line: Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy.Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy.This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, University of Catania, Catania, Italy.

ABSTRACT
Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.

No MeSH data available.


Related in: MedlinePlus